Photo by Daniel H. Tong on Unsplash
News /

Gynuity President Presents Alongside Leading Global Experts on Abortion at the FIGO World Congress 2021

Gynuity president, Beverly Winikoff, will give a presentation and co-chair a Special Session at the FIGO World Congress. She shares the virtual platform with leading experts in reproductive health from around the world.

Thursday, October 28, 2021
3–4pm Pacific Daylight Time / 6 –7pm Eastern Daylight Time / 11pm – Midnight British Summer Time
Organized by:
Beverly Winikoff, Gynuity Health Projects, USA and Caroline De Costa, James Cook University, Queensland, Australia

Self-Managed and “No-Test” Abortion Beverly Winikoff, Gynuity Health Projects, USA

Expanding the Provider Base to Increase Abortion Access Worldwide Bela Ganatra, World Health Organisation, Switzerland

Abortion from Very Early to Much Later Kristina Gemzell Danielsson, Karolinska Institute, Sweden

The Continuing Relevance of Vacuum Aspiration in Induced Abortion Nozer Sheriar, Consultant Obstetrician and Gynecologist, India

Registered congress attendees will be able to tune in live or watch the recorded session on-demand (available from the congress library until December 31).


Self-managed and “no-test” medical abortion have been widely practiced informally in communities around the world -- with most of the data on these practices either uncollected or hidden. The COVID-19 pandemic created an environment in which innovative service delivery of abortion pills became more widespread and better documented.

Gynuity's short presentation will describe completed and ongoing research documenting the use of non-traditional medical abortion services that give individuals more agency and require less contact with the medical system. Examples are presented from the US, UK, and Mexico.

Published Research by Gynuity and Partners on Self-Managed & “No-Test” Abortion

Chong et al. Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic. Contraception. 2021 Jul;104(1):43-48. doi:10.1016/j.contraception.2021.03.019. Epub 2021 Mar 27. PMID: 33781762.

Anger et al. Clinical and service delivery implications of omitting ultrasound before medication abortion provided via direct-to-patient telemedicine and mail. Contraception. 2021 Jul 28:S0010-7824(21)00342-5. doi:10.1016/j.contraception.2021.07.108. Online ahead of print. PMID: 34329607.

Kerestes et al. "It was close enough, but it wasn't close enough": A qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care. Contraception. 2021 Jul;104(1):67-72. doi:10.1016/j.contraception.2021.04.028. Epub 2021 Apr 30. PMID: 33933421.

Raymond et al. "False positive" urine pregnancy test results after successful medication abortion.Contraception. 2021 Jun;103(6):400-403. doi:10.1016/j.contraception.2021.02.004. Epub 2021 Feb 14. PMID: 33596414.

Beardsworth et al. Miles and days until medical abortion via TelAbortion versus clinic in Oregon and Washington, USA. BMJ Sex Reprod Health. 2021 Mar 31:bmjsrh-2020-200972. doi:10.1136/bmjsrh-2020-200972. Online ahead of print. PMID: 33789954.

Raymond et al. Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond, Contraception; June 1, 2020; Vol. 101(6): 361-366.

Raymond et al. TelAbortion: Evaluation of a direct to patient telemedicine abortion service in the United States. Contraception. 2019 Sep;100(3):173-177. doi:10.1016/j.contraception.2019.05.013. Epub 2019 Jun 4. PMID: 31170384.

Special mention. Publication by colleagues on the UK study:
Aiken et al. Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. BJOG; February 18, 2021.

Interested in talking with one of our experts? Email us at